153 related articles for article (PubMed ID: 23649869)
21. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
22. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
23. Tumour lysis syndrome with acute renal failure during imatinib therapy.
Ali R; Ozkalemkas F; Ozkan A; Ozcelik T; Ozkocaman V; Akdag I; Ozan U; Tunali A
Leuk Res; 2007 Apr; 31(4):573-4. PubMed ID: 16782190
[No Abstract] [Full Text] [Related]
24. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Nagafuji K; Matsumura I; Shimose T; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Kadowaki N; Ishikawa J; Imamura Y; Yamazaki H; Akashi K; Kanakura Y
Int J Hematol; 2019 Dec; 110(6):675-682. PubMed ID: 31538327
[TBL] [Abstract][Full Text] [Related]
25. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous tumor lysis syndrome in a patient with chronic myeloid leukemia treated successfully with allopurinol.
Gartenberg A; Winkel M; Leonard N
Am J Emerg Med; 2024 Apr; 78():242.e1-242.e3. PubMed ID: 38007380
[TBL] [Abstract][Full Text] [Related]
27. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies.
Wang Z; Jiang L; Yan H; Xu Z; Luo P
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):445-456. PubMed ID: 33618586
[No Abstract] [Full Text] [Related]
28. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
29. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
30. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Guérin A; Chen L; Ionescu-Ittu R; Marynchenko M; Nitulescu R; Hiscock R; Keir C; Wu EQ
Curr Med Res Opin; 2014 Nov; 30(11):2317-28. PubMed ID: 25025755
[TBL] [Abstract][Full Text] [Related]
31. Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
Vora A; Bhutani M; Sharma A; Raina V
Ann Oncol; 2002 Nov; 13(11):1833-4. PubMed ID: 12419759
[No Abstract] [Full Text] [Related]
32. Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.
Reinwald M; Schleyer E; Kiewe P; Blau IW; Burmeister T; Pursche S; Neumann M; Notter M; Thiel E; Hofmann WK; Kolb HJ; Burdach S; Bender HU
Biomed Res Int; 2014; 2014():637059. PubMed ID: 25025064
[TBL] [Abstract][Full Text] [Related]
33. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
34. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Holstein SA; Stokes JB; Hohl RJ
Leuk Res; 2009 Feb; 33(2):344-7. PubMed ID: 18835038
[TBL] [Abstract][Full Text] [Related]
35. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
[TBL] [Abstract][Full Text] [Related]
36. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
37. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
[TBL] [Abstract][Full Text] [Related]
38. [Imatinib therapy in chronic myeloid leukemia].
Egyed M; Kollár B; Rajnics P; Karádi E; Matolcsi A
Orv Hetil; 2008 Aug; 149(32):1509-12. PubMed ID: 18672441
[TBL] [Abstract][Full Text] [Related]
39. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
[TBL] [Abstract][Full Text] [Related]
40. [A Case of Chronic Myelogenous Leukemia That Developed Fibrous Pericarditis Owing to Nilotinib Use].
Miura S; Murase K; Sakurada A; Takada K; Iyama S; Sato T; Sato Y; Miyanishi K; Kobune M; Muranaka A; Tachibana K; Kato J
Gan To Kagaku Ryoho; 2017 Jun; 44(6):529-531. PubMed ID: 28698448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
